Lactacystin Exhibits Potent Anti-tumor Activity in an Animal Model of Malignant Glioma when Administered via Controlled-release Polymers
- 11 April 2006
- journal article
- laboratory investigation
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 77 (3) , 225-232
- https://doi.org/10.1007/s11060-005-6937-3
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Dose Escalation of Carmustine in Surgically Implanted Polymers in Patients With Recurrent Malignant Glioma: A New Approaches to Brain Tumor Therapy CNS Consortium TrialJournal of Clinical Oncology, 2003
- A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant gliomaNeuro-Oncology, 2003
- Camptothecin analogs in malignant gliomas: comparative analysis and characterizationJournal of Neurosurgery, 2003
- Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2002
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002
- Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblastsCell Death & Differentiation, 1998
- QSR1, an Essential Yeast Gene with a Genetic Relationship to a Subunit of the Mitochondrial Cytochromebc 1 Complex, Codes for a 60 S Ribosomal Subunit ProteinPublished by Elsevier ,1997
- Mechanistic Studies on the Inactivation of the Proteasome by Lactacystin in Cultured CellsJournal of Biological Chemistry, 1997
- How Proteolysis Drives the Cell CycleScience, 1996
- The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I trialJournal of Neuro-Oncology, 1995